“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

The chair of the CDC’s newly remade vaccine advisory committee said Wednesday that the committee will be reviewing existing vaccine recommendations and assessing whether people receive too ...

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60.

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, months before they were abruptly fired by U.S. Health Secretary Robert F ...

The CDC noted that, at this time, RSV vaccination is recommended as a single dose only. People who have already received an RSV vaccination are not recommended to receive another dose.

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the use of respiratory syncytial virus vaccines in adults aged between 50 and ...

The CDC adopted the panel's recommendations for the use of vaccines against respiratory syncytial virus and meningococcal disease, a serious bacterial infection, on June 25, the agency's website ...

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna shares were up 5.9% on Wednesday, while Pfizer was up 1%. GSK’s American ...